Actively Recruiting
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Led by Perspective Therapeutics · Updated on 2026-05-14
300
Participants Needed
19
Research Sites
326 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
CONDITIONS
Official Title
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with neuroendocrine tumors or meningioma confirmed by local pathology
- Patients with locally advanced, unresectable, or metastatic NETs for dose-finding or specific NET types and meningioma for dose-expansion
- Meningioma diagnosis confirmed by WHO classification grades 1 to 3
- Radiological evidence of measurable disease per RECIST v1.1 for NETs or RANO meningioma criteria within specified timeframes
- Lesions showing disease progression in the 12 months before enrollment
- Demonstrated tumor expression of SSTR using FDA-approved PET imaging agents
- ECOG performance status of 0 or 1
- HIV-positive patients allowed if CD4 count is above 350 cells/μL
- Allowed to use concurrent somatostatin analog therapy with ability to withhold therapy before treatment doses
- Progressive disease on approved therapies other than radionuclide therapy for NETs
- Meningioma patients on corticosteroids must have stable low dose before treatment
- Adequate catecholamine blockade if pheochromocytoma/paraganglioma tumors are present
- Able to understand and sign informed consent and comply with study requirements
- Life expectancy greater than 3 months
- Satisfactory organ function by laboratory testing
- Females of reproductive potential must use effective contraception and avoid egg donation starting from screening until 6 months after last dose
- Males of reproductive potential must use effective contraception and avoid sperm donation during the same period
You will not qualify if you...
- Known allergy or hypersensitivity to somatostatin analogs, SSTR imaging agents, or study drug components
- Active additional cancers requiring treatment
- Pregnancy or breastfeeding
- Recent febrile illness within 48 hours of treatment
- Use of another investigational drug within 30 days before treatment
- Prior systemic PRRT treatment
- Recent 90-Yttrium radioembolization within 6 months
- Recent external beam radiation therapy within 30 days
- Radiation dose documentation required if prior radiation treatments received
- Recent systemic anticancer therapy within 30 days except somatostatin analogs
- Major surgery within 30 days
- Untreated or unstable brain metastases for NETs
- Recent active infections requiring antifungals or antibiotics within 3 days
- Recent live attenuated vaccines within 7 days
- Severe nausea, vomiting, or diarrhea within 72 hours before first dose
- Medical conditions making participation hazardous
- History of severe allergic reactions to study drug components
- Current abuse of alcohol or illicit drugs
- Any medical or social issues likely to interfere with study participation
- QTc interval longer than 450 milliseconds in males and females
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Mayo Clinic
Jacksonville, Florida, United States, 32224
Actively Recruiting
2
Biogenix Molecular
Miami, Florida, United States, 33165
Actively Recruiting
3
The University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
4
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
5
University of Kentucky
Lexington, Kentucky, United States, 40536
Actively Recruiting
6
Johns Hopkins
Baltimore, Maryland, United States, 21287
Actively Recruiting
7
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
8
BAMF Health
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
9
Michigan Health Professionals
Troy, Michigan, United States, 48098
Actively Recruiting
10
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
11
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
12
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
13
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
14
UH Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
15
Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
16
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
17
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
18
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
19
Froedtert Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
C
ClinicalTrials at Perspectivetherapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here